Deutsche Bank
VIRX

Deutsche Bank’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Deutsche Bank’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,928
Closed -$12.6K – 3976
2023
Q1 		$12.6K Sell
7,928
-7,954
-50% -$14.5K ﹤0.01% 3763
2022
Q4 		$23.2K Hold
15,882
– – ﹤0.01% 3749
2022
Q3 		$68K Hold
15,882
– – ﹤0.01% 3498
2022
Q2 		$62K Sell
15,882
-3,799
-19% -$10.8K ﹤0.01% 3697
2022
Q1 		$94K Sell
19,681
-2,338
-11% -$7.04K ﹤0.01% 3604
2021
Q4 		$80K Buy
22,019
+1,166
+6% +$6.22K ﹤0.01% 3796
2021
Q3 		$167K Sell
20,853
-671
-3% -$6.61K ﹤0.01% 3662
2021
Q2 		$244K Buy
+21,524
New +$216K ﹤0.01% 3674
2019
Q2 		– Sell
-1,729
Closed -$73K – 5560
2019
Q1 		$73K Buy
+1,729
New +$39.2K ﹤0.01% 4433
2018
Q1 		– Hold
0
– – – 5643
2017
Q4 		– Hold
0
– – – 5180
2017
Q3 		– Hold
0
– – – 5125
2017
Q2 		– Sell
-6
Closed -$689 – 5157
2017
Q1 		$0 Buy
+6
New +$858 ﹤0.01% 5134
2016
Q4 		– Hold
0
– – – 5107
2016
Q3 		– Sell
-622
Closed -$87.8K – 5239
2016
Q2 		$71K Hold
622
– – ﹤0.01% 4257
2016
Q1 		$70K Hold
622
– – ﹤0.01% 4190
2015
Q4 		$117K Hold
622
– – ﹤0.01% 3992
2015
Q3 		$105K Sell
622
-24
-4% -$8.66K ﹤0.01% 4096
2015
Q2 		$408K Buy
+646
New +$343K ﹤0.01% 3516
2015
Q1 		– Sell
-120
Closed -$60.5K – 6086
2014
Q4 		$63K Sell
120
-58
-33% -$26.1K ﹤0.01% 5006
2014
Q3 		$266K Buy
178
+45
+34% +$65.1K ﹤0.01% 3907
2014
Q2 		$181K Sell
133
-55
-29% -$63.8K ﹤0.01% 4192
2014
Q1 		$260K Buy
188
+116
+161% +$135K ﹤0.01% 3752
2013
Q4 		$71K Sell
72
-397
-85% -$410K ﹤0.01% 4204
2013
Q3 		$486K Sell
469
-67
-13% -$71.6K ﹤0.01% 3513
2013
Q2 		$581K Buy
+536
New +$597K ﹤0.01% 3072

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank's VIRX Position: Q2 2023 in Review

Deutsche Bank sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 7,928 shares — an estimated $12.6K sold.

Deutsche Bank first reported a position in VIRX in Q2 2013 and held it in 22 quarters. The position peaked at $581K in Q2 2013. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • Deutsche Bank reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Deutsche Bank sold 7,928 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $12.6K.
  • Deutsche Bank first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
  • Deutsche Bank's Viracta Therapeutics, Inc. Common Stock position peaked at $581K in Q2 2013.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Deutsche Bank's 13F filing for Q2 2023, filed 14 Aug 2023.